Palonosetron 250micrograms/5ml solution for injection vials
Requires a prescription from a doctor or prescriber
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Palonosetron
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Palonosetron
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Palonosetron
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
7 branded products available
MHRA licensed products
View all licensed products for Palonosetron on the MHRA register
Aloxi 250micrograms/5ml solution for injection vials
Palonosetron 250micrograms/5ml solution for injection vials
Palonosetron 250micrograms/5ml solution for injection vials
Palonosetron 250micrograms/5ml solution for injection vials
Palonosetron 250micrograms/5ml solution for injection vials
WHO defined daily dose (DDD)
250 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 14 · Randomised trials: 36 · 2003–2026
Showing the 50 most relevant studies, sorted by most relevant.
R. Gralla, M. Lichinitser, S. Van der Vegt, et al.
Annals of Oncology, 2003
Wun-Ting Luo, Chia-Lun Chang, Tsai-Wei Huang, et al.
The Oncologist, 2024
- Nausea
- Vomiting
- Pyridines
Jitendra Kumar, R. Alagarsamy, B. Lal, et al.
Journal of Minimally Invasive Surgery, 2024
Xu H, Rong L, Yang S, et al.
2025
- Postoperative Nausea and Vomiting
- Antiemetics
- Gynecologic Surgical Procedures
BackgroundGynecological surgery is generally associated with a high risk of postoperative nausea and vomiting (PONV), for which a combination of antiemetic therapies is advised, but adherence to these protocols is often low. Given the current reality, a preferred 5-HT3 receptor antagonist for preventing PONV as a result of gynecological operations might be desirable. However, the efficiency of different 5-HT3 receptor antagonists in gynecological operations was not clear.ObjectiveTo assess the effectiveness of different 5-HT3 antagonists in preventing PONV after gynecological surgery.Search strategyElectronic databases, including PubMed, Embase, the Cochrane Library, and Web of Science, were searched for randomized clinical trials (RCTs) from their inception up to September 20, 2023.Selection criteriaPatients who received only 5-HT3 antagonists to prevent nausea and vomiting following gynecologic surgical procedures were included. Only RCT articles and English language literature were included.Data collection and analysisTwo investigators independently assessed the study quality and performed data extraction. R software and STATA 17 were used for this network meta-analysis to compare treatments using a frequentist approach.Main resultsPalonosetron demonstrated superior efficacy compared with ondansetron, with a significant difference in "acute nausea," "overall nausea," "acute vomiting," "late vomiting," "late PONV," "overall PONV," "late rescue medicine" and ">24 h rescue medicine." There was a significant difference between palonosetron and ramosetron in "acute nausea," between ramosetron and ondansetron in ">24 h nausea," and between granisetron and ondansetron in "late vomiting." Additionally, granisetron and palonosetron are generally ranked higher in the P-score system.ConclusionsIn gynecological surgery, palonosetron demonstrated superior efficacy to ondansetron. Granisetron seemed to be the most effective alternative to palonosetron in our study.
Abstract licence: CC BY
Xianghui Xu, Changxun Yin, Jiachun Cai, et al.
Frontiers in Medicine, 2026
Kang HY
2025
Yukinori Okada, K. Oba, N. Furukawa, et al.
The Oncologist, 2019
Atsushi Yamaguchi, Y. Saito, Y. Takekuma, et al.
Supportive Care in Cancer, 2023
2025
Zhaosheng Jin, Chao-Ying Kowa, Sophie S Gan, et al.
Current Medical Research and Opinion, 2021
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
33 found
Half-life
40 hours
Mechanism
Palonosetron is a selective serotonin 5-HT3 receptor antagonist.
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
40 hours
Protein binding
62%
Volume of distribution
2.5 L/kg
Metabolism
50%
Elimination
80%
Clearance
35 mL
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1551 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC A04AA55
ATC A04AA05
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Palonosetron
Additional database identifiers
Drugs Product Database (DPD)
21240
ChemSpider
4892289
BindingDB
50417287
PDB
O7B
ZINC
ZINC000003795819
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5297
GenAtlas
HTR3A
GeneCards
HTR3A
GenBank Gene Database
D49394
GenBank Protein Database
681914
Guide to Pharmacology
373
UniProt Accession
5HT3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2625
GenAtlas
CYP2D6
GeneCards
CYP2D6
GenBank Gene Database
M20403
GenBank Protein Database
181350
Guide to Pharmacology
1329
UniProt Accession
CP2D6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72